<- All drugs

Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Lotiglipron

INVESTIGATIONAL

oral non-peptide small-molecule GLP-1 receptor agonist

graded findings

effect domains

Evidence spread

High evidence 0Moderate evidence 0Low evidence 1Very low evidence 2

Lotiglipron is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron INVESTIGATIONAL

Pharmacology and mechanism Not directional

Low evidence

Oral non-peptide GLP-1RA (PF-07081532, Pfizer/Sosei Heptares). Two phase 1 MAD studies in T2D and obesity reported PK/PD signals. Development DISCONTINUED June 2023 on...

Buckeridge et al., Diabetes Obes Metab 2024 (phase 1); Pfizer update June 2023 Source

Full findingOral non-peptide GLP-1RA (PF-07081532, Pfizer/Sosei Heptares). Two phase 1 MAD studies in T2D and obesity reported PK/PD signals. Development DISCONTINUED June 2023 on elevated transaminases in phase 1 DDI studies and ongoing phase 2 (transaminase elevation 6.0-6.6% on lotiglipron vs 1.6% placebo, obesity cohort); no liver symptoms/failure. Pfizer noted such elevations had not been seen with danuglipron at that time.

PopulationTwo phase 1 randomised placebo-controlled MAD studies in T2D and obesity; plus ongoing phase 2

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Scope limitsno outcome data yet (ongoing)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron INVESTIGATIONAL

Safety signals Increase

Very low evidence

Elevated liver enzymes observed in clinical testing, leading to discontinuation of the entire program in 2023.

Pfizer / BioPharma Dive: Pfizer, citing safety concerns, scraps one of two obesity pill h... Source

PopulationPfizer phase 1/2 lotiglipron program (obesity and T2D)

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)

Scope limitsidentifier not fully verified

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Lotiglipron INVESTIGATIONAL

Weight change Not directional

Very low evidence

Weight-loss/glycaemic efficacy was being evaluated in mid-stage trials but development halted before mature efficacy data were published.

Pfizer press / CNBC: Pfizer to end development of experimental obesity pill lotiglipron, ... Source

PopulationPhase 1/2 (obesity, T2D); halted 2023

Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)

Scope limitsidentifier not fully verified